Kynos Therapeutics, a spin-out from the University of Edinburgh, is an immunemetabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3monooxygenase (KMO) biology.
VIEW WEBSITE >>
VIEW WEBSITE >>
Location: United Kingdom, Scotland, City of Edinburgh
Total raised: $11.76M
Investors 1
| Date | Name | Website |
| - | Epidarex C... | epidarex.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.04.2022 | Seed | $11.76M | Epidarex C... |
Mentions in press and media 2
| Date | Title | Description |
| 06.05.2022 | DIGIT Deal Roundup | April 2022 | Funding SIS Ventures Scottish impact investor SIS Ventures has secured £1m in funding for its Impact First investment fund. Impact First launched its second round of fundraising in February this year with the aim of attracting up to £5m to ... |
| 07.04.2022 | Kynos Therapeutics Raises GBP£9M in Funding | Kynos Therapeutics, an Edinburgh, Scotland, UK-based immune-metabolic company, raised GBP£9M in funding. The £6.5m equity round was led by Epidarex Capital, joined by Ip Group and Scottish Enterprise. Kynos has also been awarded £2.5m throu... |